Key Takeaways
- Librela destocking dominates FY27: The animal health drug's destocking drove FY26 growth to just 3% and will make FY27 broadly flat, with Q1 the worst hit. Management resets the baseline here and points to FY28 for stronger growth.
- Q4 sequential rebound offers proof of life: 13% QoQ growth in Q4, plus clinical trial revenue now flowing, underpins confidence that underlying momentum is intact once the Librela overhang clears.
- Margin beat came from mix, not magic: FY26 EBITDA margin landed at 25% vs 22-23% guidance, driven by a favorable product mix shift and some costs moving to exceptional items, not a structural step-up.
- BMS extension to 2035 is the strategic anchor: The decade-long horizon lets both parties invest in new modalities and AI-led discovery, though near-term revenue growth is pegged only to US inflation.
- What to watch next quarter: Whether the Q1 Librela trough is as deep as feared, any early signs of Bayview customer commitments, and how the new CEO and Executive Chairperson reshape the commercial engine.
The Librela Overhang: Sizing the Hole
- FY26 damage: Librela destocking materially suppressed top-line growth to 3% for the full year. Excluding Librela from both FY25 and FY26, underlying growth was high-single digits.
- FY27 trajectory: Q1 and Q2 will have almost no Librela revenue. Only a minor volume is expected toward the end of the year, with no incremental revenue plans beyond that small tail.
- The reset logic: Management frames FY27 as a strategic reset year where the Librela headwind is absorbed and the baseline is cleaned. The exit from FY27 is expected to be on a growth trajectory, with the Librela effect fully washed out by then.
- Zoetis follow-on (Lenivia): Syngene has no participation in the commercial production of the follow-on molecule. Some clinical work was done and conversations continue, but nothing is committed.
Bains: "Getting back to more sustainable growth and to higher growth levels is clearly the direction that we're looking to build Syngene. The Librela headwinds have clearly had material impacts last year '26... And we would expect to end '27 on a growth trajectory and the Librela effect will then have washed out."
Margin Mechanics: The Beat and the Path Forward
- Q4 margin walk: EBITDA margin fell to 29% from 34% YoY. Staff costs rose 19% YoY, other direct costs rose 17% (new Bayview and Bangalore biologics facilities), and a hedge loss of ₹21 cr compounded the pressure. Cost optimization (other expenses down 9%) partially offset.
- Full-year beat explained: The 25% delivered vs 22-23% guidance came from two factors: a favorable shift in the assumed product mix and its cost structure, plus some costs landing in exceptional items rather than operating expenses.
- Exceptional items: Termination benefits of ~₹25 cr net of tax were recognized under exceptional items for organizational rebalancing. A gratuity remeasurement credit of ₹20 cr net of tax also landed here, linked to reassessment under new labour codes.
- Cost rebalancing: People costs rose early in the year from investments, then some rebalancing was needed in parts of the organization. Management declined to elaborate beyond what was in the notes.
- FY27 margin guidance: Mid-20s EBITDA margin, with Bayview costs baked in. Management aspirationally wants to improve margins as utilization curves on sites improve, but is guiding only for the year at mid-20s and declined to give a path to high-20s or 30%.
New Capabilities and Facilities: The Build Phase
- Bayview biologics facility: Preparations progressing well, active customer engagement underway, moving toward operationalization this year. Initial trial runs expected in the coming year; capitalization will follow regulatory approvals. The facility is not yet fully capitalized and remains a partial P&L drag.
- ADC discovery lab: A state-of-the-art antibody drug conjugate discovery laboratory commenced operations in Q4, designed for early-stage research and complementing existing ADC development and manufacturing capabilities.
- GMP bioconjugation suite: Added at the Bangalore biologics facility, enabling fully integrated end-to-end ADC manufacturing (mAb production plus GMP bioconjugation at a single site).
- Liquid-filled hard gelatin capsules: A new commercial-scale facility was commissioned, strengthening the oral solid dosage capability.
- Gestation reality: New CDMO capacities like Unit 3 and Bayview typically take 12-24 months from acquisition to regulatory approval and capitalization. Unit 3 took ~18 months to become operational.
- Peptide ADC and capsules contribution: These new capabilities are expected to contribute to the pipeline build and help exit FY27 on a growth trajectory, with more sustained growth in FY28 after the Librela impact clears.
The BMS Anchor and CDMO Ambition
- BMS extension to 2035: The long-standing partnership now has a 10-year horizon, broadening scope across discovery, translational sciences, pharmaceutical development, manufacturing, and clinical research.
- Strategic, not linear: Management was explicit that growth will not be linear and is expected to grow around US inflation at some level. The extension enables strategic thinking and collaboration on new modalities and AI in discovery and development.
- CDMO focus: Management is focusing on the CDMO business for more aggressive and sustainable growth. The revenue split outlook remains directionally two-thirds CRO, one-third CDMO, with minor changes possible.
Bains: "I think it's really -- the time horizon enables strategic thinking. And of course, if we look at the market outside and developments in these new modalities that we've discussed... it really allows the parties, Bristol-Myers Squibb and Syngene to think strategically."
Leadership and Strategic Reset
- Executive Chairperson: Kiran Mazumdar-Shaw has taken an executive role to lead Syngene through what she calls a transition from a traditional services model to a more value-added, technology-led partnership model.
- New CEO: Siddharth (from Biocon Generics) appointed as CEO for full-time presence in India. Abhijit (also from Biocon Generics) brings commercial and business development experience.
- AI investment: Syngene has a team of AI scientists working on applying algorithms to enhance service offerings and is investing in new AI capabilities, with management seeing profound implications for discovery, development, and manufacturing.
- Research services growth: All three legs (chemistry, biology/biotherapeutics, translation/clinical) are expected to grow. Biotherapeutics has a clear opportunity; the translation and clinical research business is looking at significant expansion as clinical trials pick up in India. Management declined to split these quantitatively.
Mazumdar-Shaw: "I'm someone who has worked with them very closely for over many, many years. Obviously, I'm happy to be back to take Syngene through this very exciting time. And this is a team I'm very familiar with, and I'm very confident that we will reset and rebuild the Syngene model in all the particular areas that we spoke about."
External Risks: Tariffs, Middle East, and Cost Pass-Through
- Tariff impact: Management's assessment is that the impact on Syngene is negligible. The company is still receiving RFPs from prospective customers.
- Middle East conflict: No material impact on continuity of service so far. Syngene is reengineering distribution and logistics and talking to customers contract-by-contract. On whether cost pass-through is easier in CRO vs CDMO, management said it is not one-size-fits-all and depends on the nature of the conversation.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Broadly flat performance | FY27 |
| H1 vs H2 weighting | H1 muted; H2 meaningfully stronger as new contracts ramp up | FY27 |
| Q1 Librela impact | More pronounced adverse impact of destocking | Q1 FY27 |
| Librela volumes | Almost no Librela in Q1 and Q2; minor volumes toward year-end | FY27 |
| Librela exit | Librela effect fully washed out; exit year on a growth trajectory | End of FY27 |
| EBITDA margin | Mid-20s, with Bayview costs baked in | FY27 |
| Stronger growth | Healthy deal pipeline translates into stronger growth | FY28 onwards |
| Bayview biologics | Moving toward operationalization; initial trial runs expected | FY27 |
| BMS contract | Extended through 2035; growth around US inflation at some level | 10-year horizon |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue from operations | ₹1,037 cr, +2% YoY and +13% QoQ |
| Full year revenue growth | 3% YoY |
| Underlying revenue growth ex-Librela | High-single digits (FY26) |
| Operating EBITDA | ₹303 cr, margin 29% vs 34% in Q4 FY25 |
| Full year operating EBITDA margin | 25% |
| Profit after tax before exceptional items | ₹153 cr, down 16% YoY |
| Reported profit after tax | ₹148 cr, down 19% YoY, after ₹25 cr termination benefits and ₹20 cr gratuity credit |
| Free cash flow | ₹521 cr (FY26) |
| Net cash balance | ₹1,800 cr as of March 31, 2026 |
| Revenue split | 59% research services, 41% CDMO (Q4); full year approx two-thirds CRO, one-third CDMO |
| FY27 revenue guidance | Broadly flat |
| FY27 EBITDA margin guidance | Mid-20s |
| Q4 capex | $10M, approx 50% research services, 40% CDMO, rest digitization/automation/infrastructure |
| Q4 normalized effective tax rate | 24.2% vs 23.7% in Q4 FY25 |